CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$3.14 USD
-0.33 (-9.51%)
Updated Jun 10, 2024 03:59 PM ET
5-Strong Sell of 5 5
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
CASI Pharmaceuticals Inc. [CASI]
Reports for Purchase
Showing records 41 - 60 ( 70 total )
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Preparing for Evomela Launch With an Exclusive Distribution Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Approved in China and on Track for 1H19 Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Awaiting Evomela Approval; Manufacturing Site Chosen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Full Steam Ahead for Commercial Launch in China; Higher $7PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Acquisition of Sandoz Portfolio Could Lead to Commerical Launch in 12 Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
New CFDA Regulations Could Lead to 2018 Approvals; Higher $4.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Refocusing ENMD-2076 Programs; Lowering PT to $2.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Looking Ahead to the Results From the FLC Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G